AlphAIalphai — Financial news for AI agents
pro.thestreet.comAUG 213 min read$MRNA

After Moderna’s Big News, Here Are Three Biotechs to Watch

Moderna (MRNA) and Merck (MRK) rose sharply after positive Phase 3 trial data for a skin cancer therapy. Biotech sector, up 40% YTD, saw gains. Aurinia (AUPH) settled litigation with Teva (TEVA), removing uncertainty. Ocular (OCUL) received positive analyst ratings. Precigen (PGEN) reported strong Q2 revenue and expects cash flow breakeven by year-end.

Original reporting
pro.thestreet.com
Published Aug 21, 2026, 3:45 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 21, 2026, 9:44 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
After Moderna’s Big News, Here Are Three Biotechs to Watch — source image
Source · pro.thestreet.com
Decision brief

The 30-second read

$MRNABullishHigh
01

Why it matters

These events collectively boost sector sentiment, offering short‑term trading opportunities across the highlighted stocks.

02

Market read

Biotech sector sees a multi‑stock rally; traders can target the highlighted names for momentum plays.

03

What to watch

Potential competition in skin‑cancer space and reliance on single‑product pipelines could limit upside.

Relevance 9/10Novelty 9/10Timing: Wednesday intraday

Background

The article reviews recent biotech catalysts, highlighting a rally driven by trial data and legal settlements.

Company-level read

Ticker impact

$MRNABullishHigh confidence
Context

Moderna disclosed positive Phase 3 skin cancer trial data, driving a 175% intraday price surge.

Expected impact

Expect continued upside on regulatory progress; target $250 if approval path remains clear.

Evidence & confidence

Large-cap biotech with breakthrough data and massive price move indicates strong market reaction.

$MRKBullishMedium confidence
Context

Merck reported positive Phase 3 skin cancer trial results, lifting the stock over 12%.

Expected impact

Potential incremental rally to $150 as investors price in future sales.

Evidence & confidence

Mid-cap biotech with solid trial outcome; move is notable but less dramatic than Moderna.

$AUPHBullishMedium confidence
Context

Aurinia settled a litigation with Teva, securing exclusivity on Lupkynis until 2036 and received an upgrade.

Expected impact

Short-term upside to $22 as analysts raise targets.

Evidence & confidence

Legal win and analyst upgrade provide clear catalyst for share appreciation.

$OCULBullishLow confidence
Context

Ocular Therapeutix received reiterated buy ratings after competitor missed endpoint and its own Phase 3 wet AMD data.

Expected impact

Potential modest rally to $30 on continued analyst support.

Evidence & confidence

Analyst sentiment shift without new data; impact likely limited.

$PGENBullishMedium confidence
Context

Precigen highlighted strong Q2 sales of Papzimeos ($53M) and outlook for cash‑flow breakeven by year‑end.

Expected impact

Possible move toward $8‑$9 as investors price in profitability timeline.

Evidence & confidence

Solid earnings beat for a small-cap biotech; market may reward near‑term performance.

Market effects

Sector

Biotech sector gains momentum as multiple companies report positive trial data and legal wins.

Regional

U.S. biotech indices likely to outpace broader market today.

Global

Positive biotech news may lift global health‑care ETFs and attract foreign capital.

Counterpoint

What could challenge this read

Rapid price spikes may be overbought; caution on potential regulatory setbacks.

Key entities

  • company
    Moderna

    Biotech firm with positive Phase 3 skin cancer data.

  • company
    Merck

    Pharma giant with supportive trial results.

  • company
    Aurinia Pharmaceuticals

    Secured exclusivity on Lupkynis via settlement.

  • company
    Ocular Therapeutix

    Received buy rating reiterations after competitor miss.

  • company
    Precigen

    Reported strong sales of Papzimeos and breakeven outlook.

Read at source← All news

Related articles

AUG 21
$MRNAHighAI 8/10

Time High on 10.32% Session After Moderna Phase 3 Win

ARK Genomic Revolution ETF (ARKG) surged 10.32% to a record $47.67 after Moderna and Merck's mRNA cancer therapy succeeded in a Phase 3 trial. Moderna rose 177% to $174.38, Merck gained 13%. ARKG's top holdings, including Tempus AI (+23.91%), drove gains. The fund is up 64% YTD, 90% in 12 months.

tradingnews.com3 min
AUG 21
$MRKHighAI 8/10

Why Is Merck Stock Still An Undervalued Mega-Cap In Pharma?

Merck (MRK) stock surged 73% in the past year, outpacing the S&P 500, driven by successful clinical trials and FDA approvals. The company's pipeline, including LIPFENDRA and an mRNA cancer vaccine, addresses concerns about KEYTRUDA's patent expiration. Merck's forward P/E of 16x is lower than peers like Johnson & Johnson (JNJ) and Eli Lilly (LLY), suggesting potential undervaluation.

forbes.com2 min
AUG 21
$ROSTMed

Stocks making the biggest moves midday: Moderna, Robinhood, BJ's Wholesale, Coinbase & more

BJ's Wholesale shares rose 4% after Q2 earnings beat estimates, with revenue at $6.09B and EPS guidance raised. Ross Stores also gained over 4% on strong Q2 results and upbeat Q3 guidance. Crypto-related stocks like Robinhood and Coinbase surged as bitcoin climbed over 20% for the week. Broadcom rose 1% on reports of a $60B debt plan for a deal. OSI Systems dropped 10% after missing revenue expectations. The Boston Beer Company fell 3% following CFO departure news. O-I Glass jumped 10% after a C

cnbc.com3 min
AUG 21
$MRKMedAI 8/10

Merck stock analysis: great pipeline at a stretched valuation

Merck (MRK) hit an all-time high of $153.53, up 78% in a year, after positive Phase 3 results for its mRNA cancer therapy with Moderna. Analysts are divided, with Goldman Sachs raising its target to $160 and UBS downgrading to Neutral at $150. Merck's revenue grew from $48.7B (2021) to $65.0B (2025), but it trades 7.5% above fair value with a high P/E of 55.2x. The stock is in overbought territory, with technical indicators suggesting potential exhaustion.

investing.com3 min
AUG 21
$MRNAMedAI 8/10

A ‘pivotal moment’ for personalised cancer vaccines

Moderna and Merck announced positive final-stage trial results for a personalized mRNA cancer vaccine, showing increased cancer-free survival in melanoma patients when combined with Keytruda. The vaccine, tailored to each patient's tumor, uses mRNA technology. Moderna's shares surged, but experts caution pending full data release and peer review. The companies are also testing similar vaccines for other cancers.

theweek.com3 min
AUG 21
$MRKHighAI 9/10

Why is Merck stock surging to a 52-week high today?

Merck (MRK) stock rose 3.4% to a 52-week high of $154.49 after positive Phase 3 trial results for its cancer vaccine. Analysts upgraded MRK and raised price targets, citing long-term growth prospects. Broader market gains were modest but supportive. Sector peers also gained on renewed confidence in mRNA technology.

investing.com2 min